News - Votrient

Filter

Current filters:

Votrient

Popular Filters

Australian patients benefit from PBS changes; cancer research

27-02-2014

New medicines for glaucoma, diabetes and advanced soft tissue sarcoma have been approved for listing…

Asia-PacificAustraliaDiabetesFinancialHealthcareKombiglyzeOncologyPharmaceuticalResearchTrajentaVotrient

Afinitor disappoints in advanced liver cancer Ph III study

07-08-2013

Results of a global Phase III study showed that Afinitor (everolimus) did not extend overall survival…

NovartisOncologyPharmaceuticalResearchVotrient

GlaxoSmithKline files for expanded use for Votrient

07-08-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) says it has submitted a request to the European Medicines…

EuropeGlaxoSmithKlineOncologyPharmaceuticalRegulationVotrient

Prognosis for renal cell carcinoma market development

27-11-2012

Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

EMA approves GlaxoSmithKline's Votrient for soft tissue sarcomas

09-08-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that the European Medicines Agency has approved Votrient…

EuropeGlaxoSmithKlineOncologyPharmaceuticalRegulationVotrient

US FDA backs new indications for Votrient and Afinitor

29-04-2012

The US Food and Drug Administration last week gave its approval for new indications for currently marketed…

AfinitorGlaxoSmithKlineNorth AmericaNovartisOncologyPharmaceuticalRegulationVotrient

FDA panel backs GlaxoSmithKline sarcoma drug Votrient

21-03-2012

Providing welcome news for UK pharma giant GlaxoSmithKline (LSE: GSK), the Oncologic Drugs Advisory Committee…

GlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationVotrient

New Zealand to fund new cancer drugs Tykerb and Votrient

05-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, says it is funding two new targeted cancer…

Asia-PacificGlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTykerbVotrient

Three “targeted” cancer drugs slightly raise fatal side effects risk, says Dana-Faber Inst

08-02-2012

2 Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated…

NexavarOncologyPharmaceuticalResearchSutentVotrient

Robust growth forecast for renal cell carcinoma market

11-12-2011

The renal cell carcinoma drug market will experience robust 3.7% annual growth from 2010 to 2020 in the…

axitinibdovitinibGlaxoSmithKlineMarkets & MarketingNephrology and HepatologyNovartisOncologyPfizerPharmaceuticalSutentVotrient

GlaxoSmithKline files for expanded Votrient use in USA and Europe

08-07-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has submitted a variation to the Marketing Authorisation…

EuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationVotrient

Back to top